Develops drugs for pharmaceutical and biotechnology companies.
Dec 2025Revenue $8.25B/yrExpenses $7.81B/yr
No trend
Figures by year
Is Icon profitable?
Yes. In the 12 months to Dec 2025, revenue was $8.25B and expenses $7.81B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $8.25B | $7.81B | $443M |
| Dec 2024 | $8.19B | $7.16B | $1.03B |
| Dec 2023 | $8.05B | $7.15B | $905M |
| Dec 2022 | $7.74B | $6.95B | $795M |
| Dec 2021 | $5.48B | $5.10B | $379M |
| Dec 2020 | $2.80B | $2.41B | $392M |
| Dec 2019 | $2.81B | $2.37B | $433M |
| Dec 2018 | $2.60B | $2.22B | $373M |
| Dec 2017 | $1.76B | $1.42B | $338M |
| Dec 2016 | $1.67B | $1.35B | $312M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.